TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lesion Progression After Icon Treatment in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be age 19 years and older~* Have at least two vital carious teeth with caries ranging from enamel to just into dentin.~  * If the lesion is not on a 3rd molar~ * If the lesion is not developmental.~ * If the lesion is not cavitated~* Be a regular dental attendee able to return for assessments~* Be in good medical health and able to tolerate the dental procedure~* Have no chronic periodontitis which could compromise tooth retention.~* Have normal salivary function.~* Have normal bone levels~* No lingering cold sensitivity~* No periapical sensitivity~* No sensitivity to percussion~Exclusion Criteria:~* Do not meet the inclusion criteria~* Are not able to tolerate the time required for the study~* There is a history of an adverse reaction to any materials used in the study~* They are irregular dental attendees~* They maintain an unacceptable standard of oral hygiene.~* They have chronic periodontitis~* There is severe salivary gland dysfunction or reduced salivary flow is observed~* They are unable to return for recall appointments

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Resin infiltration (Type: EXPERIMENTAL): One proximal caries lesion (split mouth design) per patient will be treated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions.
- Mock treatment (Type: SHAM_COMPARATOR): A second proximal caries lesion of each patient (split mouth design) will receive a placebo treatment to mimic resin infiltration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acoustic Reflection Method and Work of Breathing

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children aged 0 to 15 years old,~* in a stable state,~* presenting an UAO which requires an endoscopic evaluation under general anaesthesia~* signed informed consent~* affiliation to french health benefits~Exclusion Criteria:~* UAO due solely to a hypertrophy of the adenoids and/or the tonsils,~* patients with a tracheostomy or a non operated cleft palate

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Children with upper airway obstruction
- 2 (Type: ACTIVE_COMPARATOR): Children without upper airway obstruction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed last on-treatment visit of the lead-in study RVT-101-3001~Exclusion Criteria:~* Any clinically relevant concomitant disease, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 86 Years
- Healthy Volunteers: f

Study Arms:
- RVT-101 35 mg tablets (Type: EXPERIMENTAL): once daily, oral tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DESolve® X-Pand Global Post Market Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Minimal age 18 years~2. Patient is willing/able to cooperate with study procedures and required follow up visits. Patient or legal representative has been informed \& agrees by signing EC approved written consent. Consent can occur before implantation of the DESolve scaffold (planned procedure) or within 30 days post implantation procedure for retrospective enrollment (unplanned procedure).~3. Planned or unplanned DESolve scaffold implantation~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTCA - Desolve Scaffold (Type: None): Patients with coronary artery stenosis who have been treated with a DESolve bioresorbable coronary scaffold

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adults with unilateral or bilateral Geographic Atrophy (GA) due to Age-related Macular Degeneration (AMD)~2. BCVA of 40 letters or better using ETDRS charts~Exclusion Criteria:~1. Evidence or history of neovascular Age-related Macular Degeneration (AMD) or diabetic retinopathy~2. Significant ocular or non-ocular disease that would impact the subject's ability to participate in the study~3. Participation in another research study involving an investigational product within the previous 4 weeks or 5 half-lives whichever is longer from the screening/baseline OR received a gene/cell therapy at any time previously

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study (Proneonat)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates with intra-uterine growth delay (with weight \< 10th centile)~* Aged \>34 weeks of amenorrhoea~* For neonates \>38 weeks of amenorrhoea, weight \< 2500g~* Mother's refusal of breast feeding~* Informed consent signed by the 2 parents~* Possibility to follow newborns until age of 2~Exclusion Criteria:~* Subject not fulfilling inclusion criteria~* Severe disease (syndrome and/or congenital abnormality, deficiency of metabolism at birth)

- Gender: ALL
- Minimum Age: 34 Weeks
- Maximum Age: 39 Weeks
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): hyperproteinic milk
- 2 (Type: ACTIVE_COMPARATOR): Normoproteinic milk

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Life Quality Determinant Assessment of Fibromyalgia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age group : 20 to 60~* Male or female~* American College of Rheumatology criteria~* Social Security beneficiary~* Informed consent of the patient~* Patient informed of the medical examination prior to inclusion~* Patient residing in the Bas-Rhin area~Exclusion Criteria:~* No medical objections to performing a stress test~* Any cardio-respiratory and musculoskeletal affection preventing physical activity~* Any particular clinical form disease~* Patient in situation of exclusion~* Subject incapacity to understand informed consent~* Patient deprived of freedom or under the protection of a conservator~* Pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Rehab Institute (Type: EXPERIMENTAL): This group will do some physical activity in a specialized institute
- Club structure (Type: ACTIVE_COMPARATOR): This group will do some physical activity in a club.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years of age or older~* Histologically confirmed Glioblastoma Multiforme (GBM)~* Radiographic evidence of disease progression~* Patients must have evaluable contrast enhancing tumor~* Availability of paraffin blocks or unstained pathology slides for biomarker studies~* Karnofsky Performance Status of greater than or equal to 60%~Exclusion Criteria:~* Prior treatment with Mammalian target of rapamycin (mTOR) inhibitor~* History of another malignancy within 3 years~* Cardiac pacemaker~* Ferromagnetic metal implants other than those approves as safe for use in Magnetic resonance imaging (MRI) scanners~* Claustrophobia~* Obesity~* Unstable systemic diseases~* Elevated cholesterol or triglycerides~* Radiation therapy or cytotoxic chemotherapy \<=4 weeks prior to study enrollment. Patient must have recovered from the toxic effects of a prior chemotherapy.~* Patients must be off all enzyme inducing anticonvulsants for at least 2 week before study enrollment can occur~* Need for increasing dose of steroids. Patients on a stable or tapering dose of steroids \>=7 days were permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Surgery (Everolimus 10 mg) (Type: EXPERIMENTAL): Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
- Everolimus 10 mg + Surgery (Type: EXPERIMENTAL): Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
- Everolimus 5 mg + Surgery (Type: EXPERIMENTAL): Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
- Everolimus 0 mg + Surgery (Type: ACTIVE_COMPARATOR): Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Estrogen or progesterone receptor positive stage IIIb/IV non-small cell lung cancer~* Eligible patients will have stable disease on erlotinib monotherapy at FDA- approved doses after a minimum duration of erlotinib therapy of 2 months~* 18 years or older~* ECOG Performance Status ≤2~* Adequate Organ Function Requirements~* Adequate coagulation function~* Postmenopausal status in female patients is required and is defined as no menstrual periods for 12 month or surgical menopause~* All patients must sign a written informed consent.~Exclusion Criteria:~* Pregnant or breast-feeding women will not be entered on this study~* Patients who are currently receiving another investigational drugs~* Patients who are currently receiving other anti-cancer agents.~* Hormone replacement therapy will not be allowed and have to be stopped 1 month prior to entry into the study~* Patients who have an uncontrolled infection.~* Patients receiving less than 100mg/day of erlotinib~* Patients with evidence of progression after 2 months of erlotinib monotherapy.~* Patients with a history of bleeding diathesis (i.e., disseminated intravascular coagulation \[DIC\], clotting factor deficiency) or long-term anticoagulant therapy (other than antiplatelet therapy).~* Patients with a history of hypersensitivity to active or inactive excipients of fulvestrant (i.e. castor oil or Mannitol).~* Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Single-arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Initiated on mechanical ventilation via endotracheal tube~* Admitted to Medical Intensive Care Unit and Medical Intensive Care Unit Team (Harrison Avenue Campus, Menino Pavilion)~* Requiring mechanical ventilation for more than 48 hours~* Meets prespecified weaning criteria~Exclusion Criteria:~* Do Not Resuscitate/Do Not Intubate order~* Pregnancy~* Mechanical ventilation initiated at another hospital~* Cardiac arrest for more than 5 minutes with poor neurologic prognosis~* Tracheostomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Computer-assisted weaning (Type: EXPERIMENTAL): Group assigned to the computer-assisted weaning program
- Standard of care weaning (Type: ACTIVE_COMPARATOR): Group assigned to receive current, evidence-based, standard of care for discontinuation of mechanical ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Intra-Operative Shear Wave Ultrasound Vibrometry for Characterization of Esophageal Malignant Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old~* Scheduled to undergo esophageal reconstruction for presumed or known esophageal cancer~* Subject is able to understand the study procedures and provide informed consent.~Exclusion Criteria:~* Subject is pregnant or breast feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 65 or older (must have reached 65th birthday)~* Morphologically confirmed diagnosis of AML, excluding AML-M3~* Must have a Zubrod performance status of 0-3~Exclusion Criteria:~* Patients with known HIV infection are excluded. If HIV infection is suspected based on clinical condition, testing may be performed at the discretion of treatment team, but is not mandated prior to enrollment.~* Patients with central nervous system involvement by AML are excluded~* Patients with history of an active cancer (except basal cell and squamous cell cancers of the skin) within the previous 2 years are excluded

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Drug Treatment (Type: EXPERIMENTAL): Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Vs Single Shot Block After ACL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Male or female, aged \>16 years old~* In good general health as evidenced by medical history and deemed medically healthy enough to tolerate surgery by the patient's primary care physician~* MRI with evidence of ACL tear, and wanting to have an ACL reconstruction surgery~* Ability to take oral medication and be willing to adhere to the study intervention, including telephone calls~* Agrees to complete surveys required on the days specified between 5-9PM~Exclusion Criteria:~* Current daily opioid requirement exceeding the equivalent of 15mg morphine~* Daily prescription of corticosteroid, tricyclic antidepressant, gabapentin, or tramadol~* Carrying the diagnosis of chronic pain syndrome, uncontrolled anxiety, history of schizophrenia or related psychiatric disorders~* History of alcohol or drug abuse/addiction~* History of preexisting nerve damage in the surgical extremity~* Knee surgery (same knee) in the previous 12 weeks~* Anticipated knee surgery in the other knee planned in the ensuing 6 months~* Diabetic patients with blood sugar values exceeding 250 mg/dl in the previous month~* BMI \>40Kg/m2~* Pregnancy, which will be determined by a serum or urine HCG test on the day of surgery.~* Incarceration~* Inability to communicate with staff, including being unreachable by telephone~* Revision ACL reconstruction~* Patient reconsideration after initial agreement.~* Non-English speaking subjects

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single Shot (Type: ACTIVE_COMPARATOR): Patients will receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine
- Continuous Block (Type: ACTIVE_COMPARATOR): Patients will have a catheter inserted into the adductor canal which will be attached up to a continuous infusion pump of bupivacaine that will have a set flow rate over the next couple days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed pancreatic adenocarcinoma~  * Metastatic (stage IV) disease~* Measurable disease~* No symptomatic brain metastases~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Not pregnant or nursing~* Adequate bone marrow, liver and kidney function~* No previous or concurrent malignancies at other sites except for surgically cured carcinoma in-situ of the cervix, basal cell or squamous cell carcinoma of the skin, or other neoplasms without evidence of disease within the past 5 years~* No multiple severe diseases which would compromise safety (i.e., cardiac failure, previous myocardial infarction within the past 4 months, cardiac arrhythmia, or history of psychiatric disabilities)~* No alcohol abuse~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or metformin~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PEXG regimen + metformin (Type: EXPERIMENTAL): cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
- PEXG regimen (Type: ACTIVE_COMPARATOR): cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues